Your browser doesn't support javascript.
loading
Aloperine inhibits colorectal cancer cell proliferation and metastasis progress via regulating miR-296-5p/STAT3 axis.
Han, Wei; Kong, Desong; Lu, Qin; Zhang, Wei; Fan, Zhimin.
Afiliação
  • Han W; Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210023, China; Chinese Medicine Modernization and Big Data Research Center, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210012, China; Department of General Surgery, Nanjing Hos
  • Kong D; Chinese Medicine Modernization and Big Data Research Center, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210012, China.
  • Lu Q; Department of Proctology, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210012, China.
  • Zhang W; Department of Anesthesiology, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210012, China.
  • Fan Z; Department of Proctology, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210012, China. Electronic address: fanzm_fzhimin@163.com.
Tissue Cell ; 74: 101706, 2022 Feb.
Article em En | MEDLINE | ID: mdl-34883316
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: RNA Neoplásico / Neoplasias Colorretais / Transdução de Sinais / MicroRNAs / Proliferação de Células / Fator de Transcrição STAT3 / Quinolizidinas / Proteínas de Neoplasias Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: RNA Neoplásico / Neoplasias Colorretais / Transdução de Sinais / MicroRNAs / Proliferação de Células / Fator de Transcrição STAT3 / Quinolizidinas / Proteínas de Neoplasias Idioma: En Ano de publicação: 2022 Tipo de documento: Article